Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with advanced non-small cell lung cancer (NSCLC) by targeting key immune regulatory proteins such as CTLA-4 or PD-1/PD-L1 (23, 24). This evidence concerns the gene PROS1 and non-small cell lung carcinoma.